GlobalData on MSN16h
Newleos secures $93.5m for neuropsychiatric treatments
The company made an upfront payment and will provide success-based milestones and royalties in exchange for global rights.
BioSpace1d
Newleos Raises $93.5M to Advance Neuropsychiatric Cast-Offs from Roche
Helmed by Roche alums, Newleos Therapeutics is taking over four drugs dropped from the Swiss pharma’s pipeline in early 2024.
Longwood Fund launches anxiety drug developer with $93.5M investment
A Boston VC firm is launching a new neuroscience company with a $93M investment that aims to treat disorders including ...
BioPharma Dive1d
A brain biotech launches with Roche’s spare parts
Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...
The Pharma Letter1d
Newleos emerges with $93.5 million and CNS drugs licensed from Roche
Boston, USA-based Newleos Therapeutics, a neuroscience company co-founded by Longwood Fund and seasoned leaders in CNS drug ...
FierceBiotech1d
VC Longwood Fund unveils neuro biotech with $93M, assets licensed from Roche
Newleos Therapeutics is making its debut with $93.5 million aimed at developing safer and more effective neuroscience ...
ENDPOINTS NEWS1d
Newleos, a new biotech with $93.5M, re­pur­pos­es Roche's ex­per­i­men­tal CNS drugs
Newleos Therapeutics emerged Thursday with $93.5 million and a bundle of oral small molecules that it licensed from Roche, ...
MM&M1d
Rx Rundown: Novartis, Abcuro, SpringWorks Therapeutics and more
RxTechExam and the Pennsylvania Pharmacists Association announced a strategic partnership. Roche’s $8 billion InterMune acquisition has been handed to a specialty pharmaceutical company, Cayman ...